In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including proteins, oligonucleotides, viral vectors, and engineered cells. One area within Complex Biologics experiencing tremendous growth is oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range of diseases. Certara supported the first FDA approval of an oligonucleotide therapy as well as 23 subsequent programs. Watch this video to learn more about oligonucleotide therapeutics, and how they work.
About Our Speaker
Dr. Suzanne Minton is the Director of Content Strategy at Certara. She has 8 years of corporate marketing experience with expertise in scientific content strategy and communication. Dr. Minton also spent 5 years conducting biomedical research on HIV and cancer. She holds a BS in biology from Duke University and a PhD in pharmacology from the School of Medicine at the University of North Carolina, Chapel Hill.